In a study, researchers investigated the potential of CTX130, a CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy, in patients with advanced clear cell renal cell carcinoma (ccRCC). With limited treatment options and poor prognoses for these patients, CTX130 offers a promising alternative by targeting CD70, which is highly expressed in ccRCC and contributes to the immunosuppressive tumor microenvironment. The multicenter phase 1 COBALT-RCC study included 16 patients with a median age of 63 years, demonstrating encouraging results with 81% of patients experiencing clinical benefit, including a durable complete response in one patient lasting over 3 years.
The researchers highlighted the significance of these findings, noting that the trial showcased the longest durable response observed with an off-the-shelf CAR T-cell therapy in refractory solid tumors to date. This breakthrough underscores the importance of further exploring CD70-targeted CAR T-cell therapy in patients with ccRCC and other high-risk solid tumors, offering hope for improved treatment outcomes in populations with limited therapeutic options.
Reference: The ASCO Post Staff. Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma. The ASCO Post. Published April 9, 2024. Accessed April 23, 2024. https://ascopost.com/news/april-2024/novel-car-t-cell-therapy-may-show-benefit-in-patients-with-advanced-clear-cell-renal-cell-carcinoma/
